(TheNewswire)
-
Phase 1 development of new digitaltherapeutic platform underway
-
Pilot study in 69 patientscompleted
-
Helping cancer patients live betterwith pain
-
Improved mental health outcomes inpain management
Vancouver, British Columbia – TheNewswire - February 17, 2022 –Blackhawk Growth Corp. (CSE:BLR ) ; (CNSX:BLR.CN); (OTC:BLRZF);( Frankfurt:0JJ) (the “ Corporation ” or“ Blackhawk ”), is pleased to announce that its subsidiary, DigitalMind Technology Pty. Ltd. (“ DMT ”) has started its phase 1 development ofa digital therapeutic application designed for treating cancerpatients experiencing pain and at risk of mental health disorders. DMTexpects to complete phase 1 in Q2, 2022,
DMT’s clinical trials in cancer patients aim todevelop a mindfulness intervention that is useful in pain management. Pain, endured for any length of time unsustainably can result in lowmood and lead to depression, anxiety and other related mental healthdisorders. The mindfulness intervention will be designed to managenegative patterns of thoughts and behaviours.
With pain being one of the most common symptomsreported by nearly 70% of cancer patients 1 , DMT iscreating a digital therapeutic application and web platform betweenpatients and clinicians that can be used by patients to moreeffectively deal with pain.
Cancer pain remains a challenging symptom occurringlong after treatment completion, with a prevalence of 20-50% in cancersurvivors. 2 The burden of mental health disorders appearing as aco-morbidity in cancer patients is high with around a quarter ofcancer patients experiencing depression 3-5 . A cancer diagnosis is life changing and in itself isa source of considerable psychological and emotional distress.
Dr Russell says: “In our pilot clinical trial in 69 patients, we saw that a digitaltherapeutic was helpful in treating cancer patients cope with fear ofcancer recurrence. We are progressing well with our digitaltherapeutics platform to help cancer patients cope with pain thatwill have substantial benefit to mental health andwellbeing”.
-
Van Den Beuken-Van MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC,Janssen DJ. Update on prevalence of pain in patients with cancer:systematic review and meta-analysis. Journal of pain and symptom management. 2016;51(6):1070-1090.e1079.
-
Gallaway MS, Townsend JS, Shelby D, Puckett MC. Peer Reviewed: PainAmong Cancer Survivors. PreventingChronic Disease. 2020;17.
-
Naser AY, Hameed AN, Mustafa N, et al. Depression and Anxiety inPatients With Cancer: A Cross-Sectional Study. Frontiers inPsychology. 2021;12(1067).
-
Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety inpatients with cancer. BMJ. 2018;361:k1415.
-
Hartung TJ, Brähler E, Faller H, et al. The risk of being depressedis significantly higher in cancer patients than in the generalpopulation: Prevalence and severity of depressive symptoms acrossmajor cancer types. European Journal of Cancer. 2017;72:46-53.
About Blackhawk Growth
Blackhawk is an investment holding company looking tocreate substantial value for its shareholders through the acquisitionand development of high growth companies. It has focused itsinvestments in the health, cannabis and cannabidiol industries in bothCanada and the United States. Its portfolio of companies includes SacPharma, TERP Wholesale LLC, LeichtMind Clinics, Noble Hemp, SpacedFood, NuWave Foods, Digital Mind Therapeutics and MindBioTherapeutics, as well as a share position in Gaia Grow Corp.(CSE:GAIA).
The Company diligently posts updates through videosfrom the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk groupsupporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com .
For further information please contact:
Frederick Pels, Chief ExecutiveOfficer
(403)-991-7737
fred@ blackhawkgrowth.com
Cautionary NoteRegarding Forward-Looking Statement
All statements in this pressrelease, other than statements of historical fact, are “forward-looking information”with respect to the Company within the meaning of applicablesecurities laws, including with respect to the development of adigital therapeutic application by Digital Mind Technology Pty. Ltd.The Company provides forward-looking statements for the purpose ofconveying information about current expectations and plans relating tothe future and readers are cautioned that such statements may not beappropriate for other purposes. By its nature, this information issubject to inherent risks and uncertainties that may be general orspecific and which give rise to the possibility that expectations,forecasts, predictions, projections or conclusions will not prove tobe accurate, that assumptions may not be correct and that objectives,strategic goals and priorities will not be achieved. These risks anduncertainties include but are not limited those identified andreported in the Company’s public filings under the Company’s SEDARprofile at www.sedar.com. Although the Company has attempted toidentify important factors that could cause actual actions, events orresults to differ materially from those described in forward-lookinginformation, there may be other factors that cause actions, events orresults not to be as anticipated, estimated or intended. There can beno assurance that such information will prove to be accurate as actualresults and future events could differ materially from thoseanticipated in such statements. The Company disclaims any intention orobligation to update or revise any forward-looking information,whether as a result of new information, future events or otherwiseunless required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.